Neonatal immunization with pneumococcal conjugate vaccine in Papua New Guinea

每年有100万儿童死于肺炎球菌病，其中大多数在第三世界。许多人在婴儿期早期死亡，婴儿可能受益于出生时接种Pnc结合疫苗（PrevenarTM）。巴布亚新几内亚对医学研究的贪得无厌；telthon儿童健康研究所和西澳大利亚大学儿科学系将合作密切审查这一做法的安全性，特别是对婴儿免疫发育和对其他疫苗反应的影响。这项研究也将为巴布亚新几内亚和澳大利亚两国的科学家提供一个独特的培训机会；转让最先进的免疫学技术，并促进本区域在呼吸道感染方面的进一步合作。

One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries; transfer state-of-the-art immunological technology and stimulate further collaborations on respiratory infections in the region.